TTTakanori Takebe

Takanori Takebe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Scholar (2023,2025)

Takanori Takebe has a total of 556 co-authors. Here are the top co-authors by number of shared publications:

  • Masaki Kimura

    Cincinnati Children's Hospital Medical Center

    30 shared publications
  • Kentaro Iwasawa

    Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA

    22 shared publications
  • Yosuke Yoneyama

    Human Biology Research Unit, Institute of Integrated Research, Institute of Science Tokyo (Science Tokyo), 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; Department of Genome Biology, Graduate School of Medicine, and Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), the University of Osaka, Suita, Osaka 565-0871, Japan

    15 shared publications
  • Hiroyuki Koike

    Yokohama City University Graduate School of Medicine

    13 shared publications
  • Ran-Ran Zhang

    Department of Regenerative Medicine, Yokohama City University School of Medicine, Yokohama, Japan

    9 shared publications
  • Hideki Taniguchi

    Division of Regenerative Medicine, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Regenerative Medicine, Graduate School of Medicine, Yokohama City University, Kanazawa-ku 3-9, Yokohama, Kanagawa 236-0004, Japan

    8 shared publications

Latest Publications

  • Open Access

    Human lymphatic organoids reconstruct convergent developmental routes to functional lymphatic vessels

    by Anmin Wang, Yunpei Zhang, Zilan Li, Karen Wang, Colin P. Johnson, Donghui Xu, Wusiman Maihemuti, Nicole M. Pek, Alonso Tapia Ramos, Kentaro Iwasawa, et al.

    The lymphatic vasculature maintains fluid balance, regulates immune surveillance, and supports tissue repair, yet how human lymphatic vessels arise and acquire specialized functions remains poorly understood. Here, guided by single-cell and spatial analyses of human embryos, we found that both lateral plate and paraxial mesoderm converge on venous endothelial intermediates with cardinal vein-like characteristics prior to lymphatic specification. Informed by these developmental trajectories, we generated three-dimensional lymphatic organoids from human pluripotent stem cells through two distinct mesodermal routes. The organoids formed capillary-like vascular networks with emerging button-like junctions and distinct endothelial and stromal programs. The lymphatic organoids were transcriptionally benchmarked to human fetal lymphatic endothelium. The organoids supported immune-cell interactions and antigen accumulation and, following transplantation, exhibited interstitial tracer uptake and transport. These findings establish a platform for investigating how distinct developmental origins shape human lymphatic specification, vascular organization, and function, with applications to lymphatic disease modeling and tissue repair.

  • A third way to breathe

    by Takanori Takebe

  • Open Access

    Mesoscale maladaptation in disease organoids

    by Masashi Okamoto, Takanori Takebe

    In chronic diseases, multiple tissue components at a shared interface often deteriorate concurrently, and disease progression may depend on interactions among these failures rather than on any single defect. Multi-tissue organoid models can mimic disease-relevant pathology in vitro, but the field lacks a simple framework for comprehensive interrogation. Here, we propose mesoscale maladaptation as an operational concept for multi-tissue disease modelling, defined as a synergistic decline in interdependent functions that can occur between two or more tissue elements. To detect maladaptation, we introduce a stepwise workflow that identifies the failing tissue elements, defines directionality of potential interdependence between these elements and compares combined perturbations with single perturbations to evaluate synergistic decline. We apply this framework to intestinal neuromuscular, hepatic sinusoidal, blood–brain barrier and tumour–neural interfaces, but it can be extrapolated to other organs and systems. This framework will illuminate future directions for in vitro complex disease modelling by enriching biological insights to disentangle progressive pathology, shifting the focus from localised biological failures to concurrent multi-tissue failures that produce synergistic pathology.


  • Open Access

    Large-scale and innervated functional human gut tissues for transplantation via transient spheroid confinement

    by Holly M. Poling, Théo Noël, Akaljot Singh, Garrett W. Fisher, Konrad Thorner, Praneet Chaturvedi, Kalpana Nattamai, Kalpana Srivastava, Matthew R. Batie, Taylor Hausfeld, et al.

    Key limitations of current human gastrointestinal organoids include incomplete physiological maturation and the need for complex, time-consuming assembloid approaches to integrate a functional nervous system for transplantation. Here we present a confined culture system (CCS) method that generates large-scale, elongated and functional human small intestinal, colonic and gastric tissues with a de novo enteric nervous system (ENS). We use a 3D-printed scaffolding tray to restrict spheroid fusion and growth, promoting the spontaneous co-development of a functional ENS. Transcriptomic and electrophysiological data demonstrate selective neuromuscular function and the presence of excitatory and inhibitory neurons within the tissues. When compared to traditional methods, the CCS expedites tissue maturation for transplantation, yielding organoids that are up to ten times larger, reaching widths of 8 cm after 10 weeks, and exhibit enhanced engraftment rate. CCS organoids integrate and adapt to murine luminal environment while maintaining barrier integrity and functional capacity. The CCS methodology simplifies current protocols while accelerating the production of complex, functional and clinically relevant gut tissues.


  • Open Access

    Maternal palmitic acid overload establishes a SETD1A-dependent epigenetic memory that programs offspring susceptibility to metabolic liver disease

    by Salvador Benitah, Claudia Bigas, Josefina Martín, Masaki Kimura, Jair Dilme, Santiago Radio, Ayla Hensgens, Marc Liesa, Julie Reisz, Monika Dzieciatkowska, et al.

    Metabolic dysfunction-associated fatty liver disease (MASLD) has emerged as a major global health concern, with prevalence rising alarmingly in the pediatric population. Maternal nutrition and maternal body mass index (BMI) influence the propensity of the offspring to develop MASLD during childhood and adulthood, but the mechanisms underlying this maternal inheritance are unknown. Here, we have explored the developmental origins of MASLD, focusing on the effect of maternal nutrition and its epigenetic consequences in offspring. Using a mouse model, we demonstrate that maternal consumption of a Palmitic Acid-enriched High-Fat and high-sugar Diet (PA-HFD) during pregnancy and lactation induces stable epigenetic modifications, particularly related to H3K4me3 deposition, in the liver of male offspring through the action of the histone methyltransferase SET1a/COMPASS. This imprinting establishes a persistent transcriptional reprogramming, notably an enrichment in genes governing fatty acid β-oxidation, generating a fasted hepatocyte-like phenotype. Integrated transcriptomic, proteomic and metabolomic analyses reveal that upon re-exposure to a HFD in adulthood, this epigenetically primed hepatic state drives exaggerated metabolic responses, including lipidome reprogramming, leading to exacerbated hepatic steatosis, peroxisomal hyperactivation, oxidative stress, toxic lipid accumulation, and impaired glucose tolerance. Importantly, these gene expression and lipidome changes predict the severity of metabolic liver disease later in life, and can be recapitulated in human pluripotent stem cell-derived hepatocytes when Plamitic Acid is exposed in developmental stage. Moreover, genetic or pharmacological inhibition of SETD1A/COMPASS eliminates the priming marks, restores hepatic transcriptomic programs, and reduces circulating insulin levels and hepatic steatosis in vivo. Together, our findings identify a mechanistic epigenetic link between maternal nutrition and lifelong MASLD susceptibility and uncover a therapeutic strategy to erase the intergenerational transmission of MASLD predisposition.

  • Top Cited Papers
    Open Access

    An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

    by Xiaoxu Li, Giorgia Benegiamo, Archana Vijayakumar, Natalie Sroda, Masaki Kimura, Ryan S. Huss, Steve Weng, Eisuke Murakami, Brian J. Kirby, Giacomo V. G. von Alvensleben, et al.

    Despite advances in lipid-lowering treatment, atherosclerotic cardiovascular disease remains the leading cause of mortality, underscoring the need to address residual risk. Targeting both the synthesis and clearance of triglyceride (TG)-rich lipoproteins is a promising approach. Liver X receptor (LXR) repression can reduce plasma TG and cholesterol and improve insulin sensitivity by suppressing de novo lipogenesis and intestinal lipid absorption and enhancing clearance of TG-rich lipoproteins, but its clinical utility remains unexplored. Here we demonstrate the role of LXR inverse agonists in lipid metabolism and metabolic diseases in preclinical models and humans. Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist. In human liver organoids modeling steatohepatitis, TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression. In a randomized, placebo-controlled phase 1 clinical trial, 14-day treatment with TLC-2716 was well tolerated (primary endpoints) and resulted in placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol (secondary endpoints). In conclusion, these results highlight the tolerability and therapeutic potential of TLC-2716 as a treatment for managing dyslipidemia and reducing residual atherosclerotic cardiovascular disease risk in humans. ClinicalTrials.gov identifier: NCT05483998 .


  • Modeling immune lineage co-development in human pluripotent stem cell-derived liver organoids

    by Milad Rezvani, Susanna Quach, Kyle Lewis, Norikazu Saiki, Chuqing Xue, Masaki Kimura, Kentaro Iwasawa, Julian Weihs, Tahlil Elzobair, Hasan Al Reza, et al.


  • Open Access

    OddSNP: a predictive framework for optimizing multiplexed single-cell RNA-seq experiments

    by Rodolfo Sebastian Allendes Osorio, Toshiya Nishimura, Yuichi Shigihara, Takanori Takebe, Takahiro Nemoto

    Donor multiplexing is a powerful strategy to increase scale, lower the costs, and reduce batch effects in single-cell RNA sequencing (scRNAseq), but clear guidelines for experimental design are lacking, forcing researchers to risk costly demultiplexing failures. To address this, we introduce SNP-Information Content (SNP-IC), a quantitative metric computable from simple unpooled pilot data that accurately predicts the success of genotype-based demultiplexing. Across multiple large-scale datasets using stem cell and organoid models, we establish a robust SNP-IC threshold of approximately 50, above which cells can be reliably assigned to their donor of origin. For more challenging genotype-free approaches, we define a pairwise metric, cpSNP-IC, and demonstrate a much higher requirement of approximately 3,000. Our open-source framework, oddSNP, implements this predictive model, allowing researchers to perform in silico titrations of sequencing depth and donor complexity to optimize experimental design before committing to large-scale studies. oddSNP provides a practical framework, enabling researchers to strategically optimize sequencing depth and donor numbers to maximize experimental success while managing costs and minimizing the risk of catastrophic data loss.

  • Open Access

    Modeling antithymocyte globulin-induced microvasculopathy using human iPSC-derived vascularized liver organoids

    by Shuntaro Kawamura, Yosuke Yoneyama, Norikazu Saiki, Yunheng Wu, Chiharu Moriya, Rio Ohmura, Mari Maezawa, Yoshihiro Shimada, Yicheng Wang, Kensaku Mori, et al.


  • Safety and tolerability of intrarectal perfluorodecalin for enteral ventilation in a first-in-human trial

    by Tasuku Fujii, Yasuyuki Kurihara, Yoshihiko Tagawa, Hirofumi Nagai, Chihiro Yokota, Hiroyuki Mizuo, Takanori Takebe